Structure analysis of the receptor binding of 2019-nCoV
- PMID: 32081428
- PMCID: PMC7092824
- DOI: 10.1016/j.bbrc.2020.02.071
Structure analysis of the receptor binding of 2019-nCoV
Abstract
2019-nCoV is a newly identified coronavirus with high similarity to SARS-CoV. We performed a structural analysis of the receptor binding domain (RBD) of spike glycoprotein responsible for entry of coronaviruses into host cells. The RBDs from the two viruses share 72% identity in amino acid sequences, and molecular simulation reveals highly similar ternary structures. However, 2019-nCoV has a distinct loop with flexible glycyl residues replacing rigid prolyl residues in SARS-CoV. Molecular modeling revealed that 2019-nCoV RBD has a stronger interaction with angiotensin converting enzyme 2 (ACE2). A unique phenylalanine F486 in the flexible loop likely plays a major role because its penetration into a deep hydrophobic pocket in ACE2. ACE2 is widely expressed with conserved primary structures throughout the animal kingdom from fish, amphibians, reptiles, birds, to mammals. Structural analysis suggests that ACE2 from these animals can potentially bind RBD of 2019-nCoV, making them all possible natural hosts for the virus. 2019-nCoV is thought to be transmitted through respiratory droplets. However, since ACE2 is predominantly expressed in intestines, testis, and kidney, fecal-oral and other routes of transmission are also possible. Finally, antibodies and small molecular inhibitors that can block the interaction of ACE2 with RBD should be developed to combat the virus.
Keywords: Coronavirus; Molecular modeling; Sequence analysis; Structure analysis.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.J Biomol Struct Dyn. 2021 Jul;39(11):4015-4025. doi: 10.1080/07391102.2020.1773318. Epub 2020 Jun 4. J Biomol Struct Dyn. 2021. PMID: 32448098 Free PMC article.
-
Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.F1000Res. 2020 Jun 9;9:576. doi: 10.12688/f1000research.24074.1. eCollection 2020. F1000Res. 2020. PMID: 32802318 Free PMC article.
-
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.Cell Mol Immunol. 2020 Jun;17(6):621-630. doi: 10.1038/s41423-020-0458-z. Epub 2020 May 15. Cell Mol Immunol. 2020. PMID: 32415260 Free PMC article.
-
Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).Mini Rev Med Chem. 2021;21(6):689-703. doi: 10.2174/1389557520666201117111259. Mini Rev Med Chem. 2021. PMID: 33208074 Review.
-
Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.Mol Biol Rep. 2023 Mar;50(3):2713-2721. doi: 10.1007/s11033-022-08193-4. Epub 2022 Dec 23. Mol Biol Rep. 2023. PMID: 36562937 Free PMC article. Review.
Cited by
-
Exploring Prehospital Data for Pandemic Preparedness: A Western Brazilian Amazon Case Study on COVID-19.Int J Environ Res Public Health. 2024 Sep 18;21(9):1229. doi: 10.3390/ijerph21091229. Int J Environ Res Public Health. 2024. PMID: 39338112 Free PMC article.
-
Role of ACE2 and TMPRSS2 polymorphisms in clinical severity and outcomes of COVID-19 in Egypt.Afr J Lab Med. 2024 Aug 27;13(1):2375. doi: 10.4102/ajlm.v13i1.2375. eCollection 2024. Afr J Lab Med. 2024. PMID: 39228902 Free PMC article.
-
Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options.Front Mol Med. 2022 Oct 17;2:917201. doi: 10.3389/fmmed.2022.917201. eCollection 2022. Front Mol Med. 2022. PMID: 39157715 Free PMC article. Review.
-
3-chymotrypsin-like protease in SARS-CoV-2.Biosci Rep. 2024 Aug 28;44(8):BSR20231395. doi: 10.1042/BSR20231395. Biosci Rep. 2024. PMID: 39036877 Free PMC article. Review.
-
Evaluation of blood pressure variation in recovered COVID-19 patients at one-year follow-up: a retrospective cohort study.BMC Cardiovasc Disord. 2024 May 7;24(1):240. doi: 10.1186/s12872-024-03916-w. BMC Cardiovasc Disord. 2024. PMID: 38714940 Free PMC article.
References
-
- Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020 Jan 29 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30185... Epub ahead of print. - PMC - PubMed
-
- Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1–23. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369385/ - PMC - PubMed
-
- Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261. https://www.annualreviews.org/doi/abs/10.1146/annurev-virology-110615-04... - DOI - PMC - PubMed
-
- Li W., Moore M.J., Vasilieva N. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. https://www.nature.com/articles/nature02145 - PMC - PubMed
-
- Xiao X., Chakraborti S., Dimitrov A.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 2013;312:1159–1164. https://www.sciencedirect.com/science/article/abs/pii/S0006291X03024136?... - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous